Pfizer 2024 revenue, profit forecast disappoints

Shares of Pfizer fell Wednesday after the drugmaker forecast 2024 revenue and profit below Wall Street’s expectations, as it sees weak demand for its once-blockbuster Covid products. 

Pfizer also raised the target of its sweeping cost-cutting plan by $500 million, bringing the anticipated total to $4 billion.

The company expects 2024 revenue of $58.5 billion to $61.5 billion. Wall Street had anticipated sales of $63.17 billion, based on a survey of analysts by LSEG, formerly known as Refinitiv.  

Pfizer’s forecast suggests that revenue next year could fall or come in flat compared to 2023. The company expects full-year revenue of $58 billion to $61 billion this year.

Pfizer also said it expects $5 billion in 2024 revenue from its Covid vaccine and $3 billion in sales from its antiviral pill Paxlovid, for a total of $8 billion from Covid products. That’s far less than the $13.8 billion in combined 2024 sales analysts expected. 

“While we do not expect Covid vaccination and infection rates to change materially in 2024 versus this year, we have set our Comirnaty and Paxlovid 2024 revenue expectations lower,” Pfizer CFO Dave Denton told investors during a call Wednesday, referring to the company’s Covid products.

The pharmaceutical giant also forecast adjusted earnings in the range of $2.05 to $2.25 per share. Analysts had expected an adjusted profit of $3.16, according to LSEG. 

Notably, Pfizer expects a 40-cent per share hit from financing costs related to its $43 billion acquisition of cancer drug developer Seagen, which it plans to formally close on Thursday. 

Shares of Pfizer fell nearly 9% in morning trading after it released its forecast, hitting a 10-year-low.

Pfizer’s stock has fallen more than 40% this year and is trading below where it was at the start of the pandemic in early 2020. 

Shares of Pfizer’s German Covid vaccine partner BioNTech fell more than 3% Wednesday, while shares of its rival Moderna also slid roughly 3%.

After raking in billions of dollars…